An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR, a HER2 or a HER3 Mutation

NCT03810872 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

87

Enrollment

OTHER

Sponsor class

Conditions

Cancers Harbouring an EGFR Mutation, (Excluding Non-squamous Non- Small Cell Lung Cancer, a Registered Indication), a HER2 Mutation or a HER3 Mutation

Interventions

DRUG: Afatinib
DRUG: Paclitaxel

Sponsor

Universitair Ziekenhuis Brussel